Cargando…

Disruption of mutated BRAF signaling modulates thyroid cancer phenotype

BACKGROUND: Thyroid cancer is the most common endocrine-related cancer in the United States and its incidence is rising rapidly. Since among various genetic lesions identified in thyroid cancer, the BRAFV600E mutation is found in 50% of papillary thyroid cancers and 25% of anaplastic thyroid cancers...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hanly, Elyse K, Rajoria, Shilpi, Darzynkiewicz, Zbigniew, Zhao, Hong, Suriano, Robert, Tuli, Neha, George, Andrea L, Bednarczyk, Robert, Shin, Edward J, Geliebter, Jan, Tiwari, Raj K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976539/ https://www.ncbi.nlm.nih.gov/pubmed/24673746 http://dx.doi.org/10.1186/1756-0500-7-187

Ejemplares similares

Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells
por: Hanly, Elyse K., et al.
Publicado: (2015)

mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib
por: Hanly, Elyse K., et al.
Publicado: (2015)

PLX4032 Mediated Melanoma Associated Antigen Potentiation in Patient Derived Primary Melanoma Cells
por: George, Andrea L., et al.
Publicado: (2015)

Molecular target based combinational therapeutic approaches in thyroid cancer
por: Rajoria, Shilpi, et al.
Publicado: (2012)

Estrogen Induced Metastatic Modulators MMP-2 and MMP-9 Are Targets of 3,3′-Diindolylmethane in Thyroid Cancer
por: Rajoria, Shilpi, et al.
Publicado: (2011)

Macrophage inflammatory factors promote epithelial-mesenchymal transition in breast cancer
por: Bednarczyk, Robert B., et al.
Publicado: (2018)

Ex Vivo Derived Primary Melanoma Cells: Implications for Immunotherapeutic Vaccines
por: Suriano, Robert, et al.
Publicado: (2013)

Biguanides and targeted anti-cancer treatments
por: Hanly, Elyse K., et al.
Publicado: (2015)

Hypoxia and estrogen are functionally equivalent in breast cancer-endothelial cell interdependence
por: George, Andrea L, et al.
Publicado: (2012)

Synthetic Toll Like Receptor-4 (TLR-4) Agonist Peptides as a Novel Class of Adjuvants
por: Shanmugam, Arulkumaran, et al.
Publicado: (2012)

Gene master regulators of papillary and anaplastic thyroid cancers
por: Iacobas, Dumitru A., et al.
Publicado: (2017)

Endothelial progenitor cell biology in disease and tissue regeneration
por: George, Andrea L, et al.
Publicado: (2011)

Androgen Receptor Activation Induces Senescence in Thyroid Cancer Cells
por: Gupta, Anvita, et al.
Publicado: (2023)

Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression
por: Anelli, Viviana, et al.
Publicado: (2017)

Androgen Activity Is Associated With PD-L1 Downregulation in Thyroid Cancer
por: O’Connell, Timmy J., et al.
Publicado: (2021)

MEG3 Expression Indicates Lymph Node Metastasis and Presence of Cancer-Associated Fibroblasts in Papillary Thyroid Cancer
por: Dadafarin, Sina, et al.
Publicado: (2022)

Different Molecular Phenotypes of Progression in BRAF- and RAS-Like Papillary Thyroid Carcinoma
por: Lim, Jinsun, et al.
Publicado: (2023)

Interactome of Long Non-Coding RNAs: Transcriptomic Expression Patterns and Shaping Cancer Cell Phenotypes
por: DeSouza, Nicole R., et al.
Publicado: (2023)

Targeting BRAF in thyroid cancer
por: Espinosa, A V, et al.
Publicado: (2007)

Targeting BRAF in thyroid cancer
por: Espinosa, A V, et al.
Publicado: (2007)

BRAF in Papillary Thyroid Carcinoma
por: Lanzilotta, Salvatore Giovanni, et al.
Publicado: (2007)

Correlation of the Expression of BRAF V600E Mutation With Various Phenotypic Expressions of Thyroid Neoplasms
por: Harikrishnan, Volga, et al.
Publicado: (2021)

Novel strategies of protecting non-cancer cells during chemotherapy: Are they ready for clinical testing?
por: Darzynkiewicz, Zbigniew
Publicado: (2011)

Another "Janus paradox" of p53: induction of cell senescence versus quiescence
por: Darzynkiewicz, Zbigniew
Publicado: (2010)

Running m(o)TOR with the brakes on leads to catastrophe at mitosis
por: Darzynkiewicz, Zbigniew
Publicado: (2012)

Perturbation of nucleotide metabolism - the driving force of oncogene-induced senescence
por: Darzynkiewicz, Zbigniew
Publicado: (2013)

Rapid and simple detection of gero-suppressive agents
por: Darzynkiewicz, Zbigniew
Publicado: (2015)

microRNA-494 and ATF3 the targets of onconase(?)
por: Darzynkiewicz, Zbigniew
Publicado: (2016)

Tumorigenesis of Papillary Thyroid Cancer Is Not BRAF-Dependent in Patients with Acromegaly
por: Kim, Hee Kyung, et al.
Publicado: (2014)

BRAF Testing in Multifocal Papillary Thyroid Carcinoma
por: Kimbrell, Hillary Z., et al.
Publicado: (2015)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

Low dose radiation regulates BRAF-induced thyroid cellular dysfunction and transformation
por: Kaushik, Neha, et al.
Publicado: (2019)

Rare Manifestations of Anaplastic Thyroid Carcinoma: the Role of BRAF Mutation Analysis
por: Song, Young Shin, et al.
Publicado: (2017)

Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
por: Notarangelo, Tiziana, et al.
Publicado: (2017)

RAF inhibitor PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling
por: Yao, Zhan, et al.
Publicado: (2018)

Snail-1 Overexpression Correlates with Metastatic Phenotype in BRAF(V600E) Positive Papillary Thyroid Carcinoma
por: Wieczorek-Szukala, Katarzyna, et al.
Publicado: (2020)

Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
por: Crespo-Rodriguez, Eva, et al.
Publicado: (2020)

The Utility of BRAF Testing in the Management of Papillary Thyroid Cancer
por: Melck, Adrienne L., et al.
Publicado: (2010)

Epigenetic modification and BRAF gene mutation in thyroid carcinoma
por: Huang, Guo, et al.
Publicado: (2021)

Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis
por: Kim, Woon Won, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fvdm81rdsa76tcm66emi3isu82